CompletedEarly phase 1Optic neuritisNCT01987167

What it found

Result in a paper, not read yet

A paper reports the results; we have not read it yet. See Papers below.

What was tested

Treatment tested

  • Corticotropin

    Melanocortin receptor 2 agonist

What it measured

Main measures

  • Neuro-protection

    12 months

    Vision

Other measures (1)

  • Preservation of retinal nerve fiber layer.

    12 months

    Retina scans (OCT)

Who could take part

Optic neuritis · 18 and over

Inclusion Criteria: * unilateral acute demyelinating optic neuritis * Able to provide informed consent * age 18 or older * can perform the above listed electrophysiologic diagnostic testing * can perform high and low contrast visual acuity and visual field perimetry Exclusion Criteria: * prior diagnosis of remitting/relapsing multiple sclerosis(RRMS) * secondary progressive MS(SPMS) * primary progressive MS (PPMS) * undergoing treatment with medications approve for treatment of RRMS(except corticosteroids for a condition not involving central nervous system demyelination) * prior diagnosis of systemic lupus erythematosis * mixed connective tissue disease * vasculitis * sarcoidosis * neuro-myelitis optica

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

The goal of the study is to determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.

Papers

Loading reviews and guidelines…

Related trials

History

    1. Started

      Nov 2013

    2. Main results due

      Dec 2016

    3. Finished

      Dec 2016

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error